小中大
疑夕的博客里认为的销售额,转载过来看看:
The first domestically developed RTK inhibitor, icotinib, achieved an annual sale of RMB 475 million in 2013. Many analysts forecast the peak annual sales of apatinib will be RMB 1 billion. Considering the limited overall survival of patients with advanced gastric cancer, I think RMB 5 million may be the ceiling.
我觉得500万可能少了点,不过5000万最多了吧?!